Intellipharmaceutics International Inc. (IPCIF)
Chart Events
Performance Outlook
| Previous Close | 0.0769 |
| Open | 0.0710 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0769 - 0.0769 |
| 52 Week Range | 0.0600 - 0.1600 |
| Volume | |
| Avg. Volume | 4,031 |
| Market Cap | 2.545M |
| Beta (5Y Monthly) | 1.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1080 |
| Earnings Date | Oct 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Intellipharmaceutics Announces Third Quarter 2022 Results
- Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI)("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2022.
- ACCESSWIRE
Intellipharmaceutics Signs an Exclusive License & Supply Agreement with Taro Pharmaceuticals Inc. for Desvenlafaxine Extended-Release Tablets
Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI)("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that it has entered into a license and supply agreement with Taro Pharmaceuticals Inc. ("Taro"), by which the Company has granted Taro an exclusive license to
- ACCESSWIRE
Intellipharmaceutics Announces Second Quarter 2022 Results
Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI)("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended May 31, 2022. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
